Is Kava (Piper methysticum) Legal in Utah? (2026)

Instrument

Controlled substance definition and controlled substances (federal schedules incorporated)

Source

https://le.utah.gov/xcode/Title58/Chapter37/C58-37_2026050620260701.pdf

Retrieved

2026-11-06

Fingerprint

50f716ce90997667

(e)
        (i) “Controlled substance” means a drug or substance:
           (A) included in Schedules I, II, III, IV, or V of Section 58-37-108;
           (B) included in Schedules I, II, III, IV, or V of the federal Controlled Substances Act, Title II,
               P.L. 91-513;
           (C) that is a controlled substance analog; or
           (D) listed in Section 58-37-109.

58-37-107 Controlled substances.

                                                   Page 10
Utah Code

    (1) All substances listed in Section 58-37-108 or 58-37-109 are controlled.
    (2) All substances listed in the federal Controlled Substances Act, Title II, P.L. 91-513, are
        controlled.

Instrument

Controlled substance analog definition and unlawful possession or use

Source

https://le.utah.gov/xcode/Title58/Chapter37/C58-37_2026050620260701.pdf

Retrieved

2026-11-06

Fingerprint

b63b983ce62e2b82

(f)
        (i) “Controlled substance analog” means:
           (A) a substance the chemical structure of which is substantially similar to the chemical
               structure of a controlled substance listed in Schedules I and II of Section 58-37-108, a
substance listed in Section 58-37-109, or in Schedules I and II of the federal Controlled
               Substances Act, Title II, P.L. 91-513;
           (B) a substance that has a stimulant, depressant, or hallucinogenic effect on the central
               nervous system substantially similar to the stimulant, depressant, or hallucinogenic
               effect on the central nervous system of controlled substances listed in Schedules I and
               II of Section 58-37-108, substances listed in Section 58-37-109, or substances listed in
               Schedules I and II of the federal Controlled Substances Act, Title II, P.L. 91-513; or
           (C) a substance that, with respect to a particular individual, is represented or intended to
               have a stimulant, depressant, or hallucinogenic effect on the central nervous system
               substantially similar to the stimulant, depressant, or hallucinogenic effect on the central
               nervous system of controlled substances listed in Schedules I and II of Section 58-37-108,
               substances listed in Section 58-37-109, or substances listed in Schedules I and II of the
               federal Controlled Substances Act, Title II, P.L. 91-513.

76-18-207 Unlawfully possessing or using a controlled substance or controlled substance
    analog.
    (1)
      (a) As used in this section:
        (i) “Correctional facility” means the same as that term is defined in Section 64-13-1.
        (ii) “Good faith” does not include seeking medical assistance under this section during the
             course of a law enforcement agency’s execution of a search warrant, execution of an arrest
             warrant, or other lawful search.
      (b) Terms defined in Sections 58-37-101, 76-1-101.5, 76-18-101, and 76-18-201 apply to this
           section.
    (2) An actor commits unlawfully possessing or using a controlled substance or a controlled
        substance analog if the actor knowingly and intentionally possesses or uses a controlled
        substance or a controlled substance analog, unless the controlled substance or controlled
        substance analog was obtained:
      (a) under a valid prescription or order;
      (b) directly from a practitioner while acting in the course of the practitioner’s professional practice;
           or
      (c) as otherwise authorized by this part or Title 58, Chapter 37, Controlled Substances.

Instrument

Utah Code 58-37-108 (Schedules; formerly 58-37-4), Schedule I (2)(a)(iii) hallucinogens; effective 7/1/2026 version

Source

https://le.utah.gov/xcode/Title58/Chapter37/C58-37_2026050620260701.pdf

Retrieved

2026-10-08

Fingerprint

819d91abcb6742f5

58-37-108 Schedules of controlled substances -- Schedules I through V -- Findings required -- Specific substances included in schedules. (1) There are established five schedules of controlled substances known as Schedules I, II, III, IV, and V, which consist of substances listed in this section. (2) Schedules I, II, III, IV, and V consist of the following drugs or other substances by the official name, common or usual name, chemical name, or brand name designated: (a) Except as provided in Subsection (3), Schedule I: (i) Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific chemical designation: (A) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N- phenylacetamide); (B) Acetyl fentanyl: (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide); (C) Acetylmethadol; (D) Acryl fentanyl (N-(1-Phenethylpiperidin-4-yl)-N-phenylacrylamide); (E) Allylprodine; (F) Alphacetylmethadol, except levo-alphacetylmethadol also known as levo-alpha- acetylmethadol, levomethadyl acetate, or LAAM; (G) Alphameprodine; (H) Alphamethadol; (I) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] propionanilide; 1- (1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine); (J) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4- piperidinyl]-N- phenylpropanamide); (K) Benzylpiperazine; (L) Benzethidine; (M) Betacetylmethadol; (N) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4- piperidinyl]-N- phenylpropanamide); (O) Beta-hydroxy-3-methylfentanyl, other name: N-[1-(2-hydroxy-2- phenethyl)-3-methyl-4- piperidinyl]-N-phenylpropanamide; (P) Betameprodine; (Q) Betamethadol; (R) Betaprodine; (S) Butyryl fentanyl (N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylbutyramide); (T) Clonitazene; (U) Cyclopropyl fentanyl (N-(1-Phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide); (V) Dextromoramide; (W) Diampromide; (X) Diethylthiambutene; (Y) Difenoxin; Page 11 Utah Code (Z) Dimenoxadol; (AA) Dimepheptanol; (BB) Dimethylthiambutene; (CC) Dioxaphetyl butyrate; (DD) Dipipanone; (EE) Ethylmethylthiambutene; (FF) Etizolam (1-Methyl-6-o-chlorophenyl-8-ethyl-4H-s-triazolo[3,4-c]thieno[2,3-e]1,4- diazepine); (GG) Etonitazene; (HH) Etoxeridine; (II) Furanyl fentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl] furan-2-carboxamide); (JJ) Furethidine; (KK) Hydroxypethidine; (LL) Ketobemidone; (MM) Levomoramide; (NN) Levophenacylmorphan; (OO) Methoxyacetyl fentanyl (2-Methoxy-N-(1-phenylethylpiperidinyl-4-yl)-N-acetamide); (PP) Morpheridine; (QQ) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine); (RR) Noracymethadol; (SS) Norlevorphanol; (TT) Normethadone; (UU) Norpipanone; (VV) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4- piperidinyl] propanamide); (WW) Para-fluoroisobutyryl fentanyl (N-(4-Fluorophenyl)-N-(1-phenethylpiperidin-4- yl)isobutyramide); (XX) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine); (YY) Phenadoxone; (ZZ) Phenampromide; (AAA) Phenibut; (BBB) Phenomorphan; (CCC) Phenoperidine; (DDD) Piritramide; (EEE) Proheptazine; (FFF) Properidine; (GGG) Propiram; (HHH) Racemoramide; (III) Tetrahydrofuran fentanyl (N-(1-Phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2- carboxamide); (JJJ) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]- propanamide; (KKK) Tianeptine; (LLL) Tilidine; (MMM) Trimeperidine; (NNN) 3-methylfentanyl, including the optical and geometric isomers (N-[3-methyl-1-(2- phenylethyl)-4-piperidyl]- N-phenylpropanamide); (OOO) 3-methylthiofentanyl (N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N- phenylpropanamide); Page 12 Utah Code (PPP) 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide also known as U-47700; and (QQQ) 4-cyano CUMYL-BUTINACA. (ii) Unless specifically excepted or unless listed in another schedule, any of the following opium derivatives, their salts, isomers, and salts of isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation: (A) Acetorphine; (B) Acetyldihydrocodeine; (C) Benzylmorphine; (D) Codeine methylbromide; (E) Codeine-N-Oxide; (F) Cyprenorphine; (G) Desomorphine; (H) Dihydromorphine; (I) Drotebanol; (J) Etorphine (except hydrochloride salt); (K) Heroin; (L) Hydromorphinol; (M) Methyldesorphine; (N) Methylhydromorphine; (O) Morphine methylbromide; (P) Morphine methylsulfonate; (Q) Morphine-N-Oxide; (R) Myrophine; (S) Nicocodeine; (T) Nicomorphine; (U) Normorphine; (V) Pholcodine; and (W) Thebacon. (iii) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances, or that contains any of their salts, isomers, and salts of isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation; as used in this Subsection (2)(a)(iii) only, "isomer" includes the optical, position, and geometric isomers: (A) Alpha-ethyltryptamine, some trade or other names: etryptamine; Monase; α-ethyl-1H- indole-3-ethanamine; 3-(2-aminobutyl) indole; α-ET; and AET; (B) 4-bromo-2,5-dimethoxy-amphetamine, some trade or other names: 4-bromo-2,5- dimethoxy-α-methylphenethylamine; 4-bromo-2,5-DMA; (C) 4-bromo-2,5-dimethoxyphenethylamine, some trade or other names: 2-(4-bromo-2,5- dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB; 2C-B, Nexus; (D) 2,5-dimethoxyamphetamine, some trade or other names: 2,5-dimethoxy-α- methylphenethylamine; 2,5-DMA; (E) 2,5-dimethoxy-4-ethylamphetamine, some trade or other names: DOET; (F) 4-methoxyamphetamine, some trade or other names: 4-methoxy-α- methylphenethylamine; paramethoxyamphetamine, PMA; Page 13 Utah Code (G) 5-methoxy-3,4-methylenedioxyamphetamine; (H) 4-methyl-2,5-dimethoxy-amphetamine, some trade and other names: 4-methyl-2,5- dimethoxy-α-methylphenethylamine; “DOM”; and “STP”; (I) 3,4-methylenedioxy amphetamine; (J) 3,4-methylenedioxymethamphetamine (MDMA); (K) 3,4-methylenedioxy-N-ethylamphetamine, also known as N-ethyl- alpha- methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, MDEA; (L) N-hydroxy-3,4-methylenedioxyamphetamine, also known as N-hydroxy-alpha- methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA; (M) 3,4,5-trimethoxy amphetamine; (N) Bufotenine, some trade and other names: 3-(β-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N, N-dimethylserotonin; 5-hydroxy-N,N- dimethyltryptamine; mappine; (O) Diethyltryptamine, some trade and other names: N,N-Diethyltryptamine; DET; (P) Dimethyltryptamine, some trade or other names: DMT; (Q) Ibogaine, some trade and other names: 7-Ethyl-6,6β,7,8,9,10,12,13-octahydro-2- methoxy-6,9-methano-5H-pyrido [1', 2':1,2] azepino [5,4-b] indole; Tabernanthe iboga; (R) Lysergic acid diethylamide; (S) Marijuana; (T) Mescaline; (U) Parahexyl, some trade or other names: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9- trimethyl-6H-dibenzo[b,d]pyran; Synhexyl; (V) Peyote, meaning all parts of the plant presently classified botanically as Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any extract from any part of such plant, and every compound, manufacture, salts, derivative, mixture, or preparation of such plant, its seeds or extracts (Interprets 21 USC 812(c), Schedule I(c) (12)); (W) N-ethyl-3-piperidyl benzilate; (X) N-methyl-3-piperidyl benzilate; (Y) Psilocybin; (Z) Psilocyn; (AA) Tetrahydrocannabinols, naturally contained in a plant of the genus Cannabis (cannabis plant), except for marijuana as defined in Subsection 58-37-101(1)(w)(i)(E), as well as synthetic equivalents of the substances contained in the cannabis plant, or in the resinous extractives of Cannabis, sp. and/or synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activity to those substances contained in the plant, such as the following: ∆1 cis or trans tetrahydrocannabinol, and their optical isomers ∆6 cis or trans tetrahydrocannabinol, and their optical isomers ∆3,4 cis or trans tetrahydrocannabinol, and its optical isomers, and since nomenclature of these substances is not internationally standardized, compounds of these structures, regardless of numerical designation of atomic positions covered; (BB) Ethylamine analog of phencyclidine, some trade or other names: N- ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl)ethylamine, N-(1- phenylcyclohexyl)ethylamine, cyclohexamine, PCE; (CC) Pyrrolidine analog of phencyclidine, some trade or other names: 1-(1-phenylcyclohexyl)- pyrrolidine, PCPy, PHP; Page 14 Utah Code (DD) Thiophene analog of phencyclidine, some trade or other names: 1-[1-(2-thienyl)- cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine, TPCP, TCP; and (EE) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine, some other names: TCPy. (iv) Unless specifically excepted or unless listed in another schedule, any material compound, mixture, or preparation that contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation: (A) Mecloqualone; and (B) Methaqualone. (v) Any material, compound, mixture, or preparation containing any quantity of the following substances having a stimulant effect on the central nervous system, including their salts, isomers, and salts of isomers: (A) Aminorex, some other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or 4,5- dihydro-5-phenyl-2-oxazolamine; (B) Cathinone, some trade or other names: 2-amino-1-phenyl-1-propanone, alpha- aminopropiophenone, 2-aminopropiophenone, and norephedrone; (C) Fenethylline; (D) Methcathinone, some other names: 2-(methylamino)-propiophenone; alpha- (methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one; alpha-N- methylaminopropiophenone; monomethylpropion; ephedrone; N-methylcathinone; methylcathinone; AL-464; AL-422; AL-463 and UR1432, its salts, optical isomers, and salts of optical isomers; (E) (±)cis-4-methylaminorex ((±)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine); (F) N-ethylamphetamine; and (G) N,N-dimethylamphetamine, also known as N,N-alpha-trimethyl-benzeneethanamine; N,N- alpha-trimethylphenethylamine. (vi) Any material, compound, mixture, or preparation that contains any quantity of the following substances, including their optical isomers, salts, and salts of isomers, subject to temporary emergency scheduling: (A) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl); and (B) N-[1- (2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl). (vii) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of gamma hydroxy butyrate (gamma hydrobutyric acid), including its salts, isomers, and salts of isomers. (viii) Unless specifically excepted or unless listed in another schedule, the following substances commonly found in Mitragyna speciosa, including synthetic versions, isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific chemical designation: (A) 7-hydroxymitragynine (methyl (E)-2[(2S,3S,7aS,12bS)-3-ethyl-7a-hydroxy-8- methoxy-2,3,4,6,7,12b-hexahydro-1H-indolo[2,3-a]quinolizin-2-yl]-3-methoxyprop-2- enoate); and (B) Mitragynine pseudoindoxyl (methyl (E)-2-[(2S,6'S,7'S,8'aS)-6'-ethyl-4-methoxy-3- oxospiro[1H-indole-2,1'-3,5,6,7,8,8a-hexahydro-2H-indolizine]-7'-yl]-3-methoxyprop-2- enoate). (b) Schedule II: (i) Unless specifically excepted or unless listed in another schedule, any of the following substances whether produced directly or indirectly by extraction from substances of Page 15 Utah Code vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis: (A) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate, excluding apomorphine, dextrorphan, nalbuphine, nalmefene, naloxone, and naltrexone, and their respective salts, but including: (I) Raw opium; (II) Opium extracts; (III) Opium fluid; (IV) Powdered opium; (V) Granulated opium; (VI) Tincture of opium; (VII) Codeine; (VIII) Ethylmorphine; (IX) Etorphine hydrochloride; (X) Hydrocodone; (XI) Hydromorphone; (XII) Metopon; (XIII) Morphine; (XIV) Oxycodone; (XV) Oxymorphone; and (XVI) Thebaine; (B) Any salt, compound, derivative, or preparation that is chemically equivalent or identical with any of the substances referred to in Subsection (2)(b)(i)(A), except that these substances may not include the isoquinoline alkaloids of opium; (C) Opium poppy and poppy straw; (D) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and any salt, compound, derivative, or preparation that is chemically equivalent or identical with any of these substances, and includes cocaine and ecgonine, their salts, isomers, derivatives, and salts of isomers and derivatives, whether derived from the coca plant or synthetically produced, except the substances may not include decocainized coca leaves or extraction of coca leaves, which extractions do not contain cocaine or ecgonine; and (E) Concentrate of poppy straw, which means the crude extract of poppy straw in either liquid, solid, or powder form that contains the phenanthrene alkaloids of the opium poppy. (ii) Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific chemical designation, except dextrorphan and levopropoxyphene: (A) Alfentanil; (B) Alphaprodine; (C) Anileridine; (D) Bezitramide; (E) Bulk dextropropoxyphene (nondosage forms); (F) Carfentanil; (G) Dihydrocodeine; (H) Diphenoxylate; (I) Fentanyl; (J) Isomethadone; Page 16 Utah Code (K) Levo-alphacetylmethadol, some other names: levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM; (L) Levomethorphan; (M) Levorphanol; (N) Metazocine; (O) Methadone; (P) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane; (Q) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic acid; (R) Pethidine (meperidine); (S) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine; (T) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate; (U) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid; (V) Phenazocine; (W) Piminodine; (X) Racemethorphan; (Y) Racemorphan; (Z) Remifentanil; and (AA) Sufentanil. (iii) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system: (A) Amphetamine, its salts, optical isomers, and salts of its optical isomers; (B) Methamphetamine, its salts, isomers, and salts of its isomers; (C) Phenmetrazine and its salts; and (D) Methylphenidate. (iv) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation: (A) Amobarbital; (B) Glutethimide; (C) Pentobarbital; (D) Phencyclidine; (E) Phencyclidine immediate precursors: 1-phenylcyclohexylamine and 1- piperidinocyclohexanecarbonitrile (PCC); and (F) Secobarbital. (v) (A) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of Phenylacetone. (B) Some of these substances may be known by trade or other names: phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl ketone. (vi) Nabilone, another name for nabilone: (±)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a- hexahydro-1-hydroxy-6, 6-dimethyl-9H-dibenzo[b,d]pyran-9-one. (vii) A drug product or preparation that contains any component of marijuana, including tetrahydrocannabinol, and is approved by the United States Food and Drug Administration and scheduled by the Drug Enforcement Administration in Schedule II of the federal Controlled Substances Act, Title II, P.L. 91-513. Page 17 Utah Code (c) Schedule III: (i) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers whether optical, position, or geometric, and salts of the isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation: (A) those compounds, mixtures, or preparations in dosage unit form containing any stimulant substances listed in Schedule II, which compounds, mixtures, or preparations were listed on August 25, 1971, as excepted compounds under Section 1308.32 of Title 21 of the Code of Federal Regulations, and any other drug of the quantitive composition shown in that list for those drugs or that is the same except that it contains a lesser quantity of controlled substances; (B) Benzphetamine; (C) Chlorphentermine; (D) Clortermine; and (E) Phendimetrazine. (ii) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a depressant effect on the central nervous system: (A) any compound, mixture, or preparation containing amobarbital, secobarbital, pentobarbital, or any salt of any of them, and one or more other active medicinal ingredients that are not listed in any schedule; (B) any suppository dosage form containing amobarbital, secobarbital, or pentobarbital, or any salt of any of these drugs that is approved by the United States Food and Drug Administration for marketing only as a suppository; (C) any substance that contains any quantity of a derivative of barbituric acid or any salt of any of them; (D) Chlorhexadol; (E) Buprenorphine; (F) any drug product containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under the federal Food, Drug, and Cosmetic Act, Section 505; (G) Ketamine, its salts, isomers, and salts of isomers, some other names for ketamine: ± -2- (2-chlorophenyl)-2-(methylamino)-cyclohexanone; (H) Lysergic acid; (I) Lysergic acid amide; (J) Methyprylon; (K) Sulfondiethylmethane; (L) Sulfonethylmethane; (M) Sulfonmethane; and (N) Tiletamine and zolazepam or any of their salts, some trade or other names for a tiletamine-zolazepam combination product: Telazol, some trade or other names for tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone, some trade or other names for zolazepam: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e] [1,4]- diazepin-7(1H)-one, flupyrazapon. (iii) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a U.S. Food and Drug Administration approved drug product, some other names for dronabinol: Page 18 Utah Code (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, or (-)- delta-9-(trans)-tetrahydrocannabinol. (iv) Nalorphine. (v) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid: (A) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium; (B) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized therapeutic amounts; (C) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium; (D) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts; (E) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized therapeutic amounts; (F) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts; (G) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts; and (H) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with one or more active, non-narcotic ingredients in recognized therapeutic amounts. (vi) Unless specifically excepted or unless listed in another schedule, anabolic steroids including any of the following or any isomer, ester, salt, or derivative of the following that promotes muscle growth: (A) Boldenone; (B) Chlorotestosterone (4-chlortestosterone); (C) Clostebol; (D) Dehydrochlormethyltestosterone; (E) Dihydrotestosterone (4-dihydrotestosterone); (F) Drostanolone; (G) Ethylestrenol; (H) Fluoxymesterone; (I) Formebulone (formebolone); (J) Mesterolone; (K) Methandienone; (L) Methandranone; (M) Methandriol; (N) Methandrostenolone; (O) Methenolone; (P) Methyltestosterone; (Q) Mibolerone; Page 19 Utah Code (R) Nandrolone; (S) Norethandrolone; (T) Oxandrolone; (U) Oxymesterone; (V) Oxymetholone; (W) Stanolone; (X) Stanozolol; (Y) Testolactone; (Z) Testosterone; and (AA) Trenbolone. (vii) Anabolic steroids expressly intended for administration through implants to cattle or other nonhuman species, and approved by the Secretary of Health and Human Services for use, may not be classified as a controlled substance. (viii) A drug product or preparation that contains any component of marijuana, including tetrahydrocannabinol, and is approved by the United States Food and Drug Administration and scheduled by the Drug Enforcement Administration in Schedule III of the federal Controlled Substances Act, Title II, P.L. 91-513. (ix) Nabiximols. (d) Schedule IV: (i) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing not more than 1 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit, or any salts of any of them. (ii) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances, including its salts, isomers, and salts of isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation: (A) Alprazolam; (B) Barbital; (C) Bromazepam; (D) Butorphanol; (E) Camazepam; (F) Carisoprodol; (G) Chloral betaine; (H) Chloral hydrate; (I) Chlordiazepoxide; (J) Clobazam; (K) Clonazepam; (L) Clorazepate; (M) Clotiazepam; (N) Cloxazolam; (O) Delorazepam; (P) Diazepam; (Q) Dichloralphenazone; (R) Estazolam; (S) Ethchlorvynol; (T) Ethinamate; (U) Ethyl loflazepate; (V) Fludiazepam; Page 20 Utah Code (W) Flunitrazepam; (X) Flurazepam; (Y) Halazepam; (Z) Haloxazolam; (AA) Ketazolam; (BB) Loprazolam; (CC) Lorazepam; (DD) Lormetazepam; (EE) Mebutamate; (FF) Medazepam; (GG) Meprobamate; (HH) Methohexital; (II) Methylphenobarbital (mephobarbital); (JJ) Midazolam; (KK) Nimetazepam; (LL) Nitrazepam; (MM) Nordiazepam; (NN) Oxazepam; (OO) Oxazolam; (PP) Paraldehyde; (QQ) Pentazocine; (RR) Petrichloral; (SS) Phenobarbital; (TT) Pinazepam; (UU) Prazepam; (VV) Quazepam; (WW) Temazepam; (XX) Tetrazepam; (YY) Tramadol; (ZZ) Triazolam; (AAA) Zaleplon; and (BBB) Zolpidem. (iii) Any material, compound, mixture, or preparation of fenfluramine that contains any quantity of the following substances, including its salts, isomers whether optical, position, or geometric, and salts of the isomers when the existence of the salts, isomers, and salts of isomers is possible. (iv) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers whether optical, position, or geometric isomers, and salts of the isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation: (A) Cathine ((+)-norpseudoephedrine); (B) Diethylpropion; (C) Fencamfamine; (D) Fenproprex; (E) Mazindol; (F) Mefenorex; (G) Modafinil; Page 21 Utah Code (H) Pemoline, including organometallic complexes and chelates thereof; (I) Phentermine; (J) Pipradrol; (K) Sibutramine; and (L) SPA ((-)-1-dimethylamino-1,2-diphenylethane). (v) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of dextropropoxyphene (alpha-(+)-4- dimethylamino-1, 2-diphenyl-3-methyl-2-propionoxybutane), including its salts. (vi) A drug product or preparation that contains any component of marijuana and is approved by the United States Food and Drug Administration and scheduled by the Drug Enforcement Administration in Schedule IV of the federal Controlled Substances Act, Title II, P.L. 91-513. (e) Schedule V: (i) Any compound, mixture, or preparation containing any of the following limited quantities of narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, which includes one or more non-narcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone: (A) not more than 200 milligrams of codeine per 100 milliliters or per 100 grams; (B) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams; (C) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams; (D) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit; (E) not more than 100 milligrams of opium per 100 milliliters or per 100 grams; (F) not more than 0.5 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit; and (G) unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation that contains Pyrovalerone having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers. (ii) A drug product or preparation that contains any component of marijuana, including cannabidiol, and is approved by the United States Food and Drug Administration and scheduled by the Drug Enforcement Administration in Schedule V of the federal Controlled Substances Act, Title II, P.L. 91-513. (iii) Gabapentin. (3) (a) As used in this subsection, "pharmaceutical composition" means a drug that has United States Food and Drug Administration approval under 21 U.S.C. Sec. 355 following clinical trials. (b) If the federal government schedules a pharmaceutical composition of a Schedule I controlled substance or a pharmaceutical composition of any form of a Schedule I controlled substance in a schedule that is not Schedule I, that pharmaceutical composition is deemed scheduled under this section in the same schedule that the pharmaceutical composition is scheduled under 21 U.S.C. Sec. 812 and 21 C.F.R. Part 1308. Renumbered and Amended by Chapter 362, 2026 General Session

Instrument

Schedule I substances

Source

https://le.utah.gov/xcode/Title58/Chapter37/C58-37_2026050620260701.pdf

Retrieved

2026-11-01

Fingerprint

46a31071bfabc52a

(2) Schedules I, II, III, IV, and V consist of the following drugs or other substances by the official
name, common or usual name, chemical name, or brand name designated:
(a) Except as provided in Subsection (3), Schedule I:
(i) Unless specifically excepted or unless listed in another schedule, any of the following
opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and
ethers, when the existence of the isomers, esters, ethers, and salts is possible within the
specific chemical designation:
(A) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-
phenylacetamide);
(B) Acetyl fentanyl:  (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);
(C) Acetylmethadol;
(D) Acryl fentanyl (N-(1-Phenethylpiperidin-4-yl)-N-phenylacrylamide);
(E) Allylprodine;
(F) Alphacetylmethadol, except levo-alphacetylmethadol also known as levo-alpha-
acetylmethadol, levomethadyl acetate, or LAAM;
(G) Alphameprodine;
(H) Alphamethadol;
(I) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] propionanilide; 1-
(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);
(J) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4- piperidinyl]-N-
phenylpropanamide);
(K) Benzylpiperazine;
(L) Benzethidine;
(M) Betacetylmethadol;
(N) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4- piperidinyl]-N-
phenylpropanamide);
(O) Beta-hydroxy-3-methylfentanyl, other name: N-[1-(2-hydroxy-2- phenethyl)-3-methyl-4-
piperidinyl]-N-phenylpropanamide;
(P) Betameprodine;
(Q) Betamethadol;
(R) Betaprodine;
(S) Butyryl fentanyl (N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylbutyramide);
(T) Clonitazene;
(U) Cyclopropyl fentanyl (N-(1-Phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);
(V) Dextromoramide;
(W) Diampromide;
(X) Diethylthiambutene;
(Y) Difenoxin;
(Z) Dimenoxadol;
(AA) Dimepheptanol;
(BB) Dimethylthiambutene;
(CC) Dioxaphetyl butyrate;
(DD) Dipipanone;
(EE) Ethylmethylthiambutene;
(FF) Etizolam  (1-Methyl-6-o-chlorophenyl-8-ethyl-4H-s-triazolo[3,4-c]thieno[2,3-e]1,4-
diazepine);
(GG) Etonitazene;
(HH) Etoxeridine;
(II) Furanyl fentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl] furan-2-carboxamide);
(JJ) Furethidine;
(KK) Hydroxypethidine;
(LL) Ketobemidone;
(MM) Levomoramide;
(NN) Levophenacylmorphan;
(OO) Methoxyacetyl fentanyl (2-Methoxy-N-(1-phenylethylpiperidinyl-4-yl)-N-acetamide);
(PP) Morpheridine;
(QQ) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
(RR) Noracymethadol;
(SS) Norlevorphanol;
(TT) Normethadone;
(UU) Norpipanone;
(VV) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4- piperidinyl] propanamide);
(WW) Para-fluoroisobutyryl fentanyl (N-(4-Fluorophenyl)-N-(1-phenethylpiperidin-4-
yl)isobutyramide);
(XX) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
(YY) Phenadoxone;
(ZZ) Phenampromide;
(AAA) Phenibut;
(BBB) Phenomorphan;
(CCC) Phenoperidine;
(DDD) Piritramide;
(EEE) Proheptazine;
(FFF) Properidine;
(GGG) Propiram;
(HHH) Racemoramide;
(III) Tetrahydrofuran fentanyl (N-(1-Phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-
carboxamide);
(JJJ) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]- propanamide;
(KKK) Tianeptine;
(LLL) Tilidine;
(MMM) Trimeperidine;
(NNN) 3-methylfentanyl, including the optical and geometric isomers (N-[3-methyl-1-(2-
phenylethyl)-4-piperidyl]- N-phenylpropanamide);
(OOO) 3-methylthiofentanyl (N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-
phenylpropanamide);
(PPP) 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide also known as
U-47700; and
(QQQ) 4-cyano CUMYL-BUTINACA.

Instrument

Schedule I, hallucinogenic substances

Source

https://le.utah.gov/xcode/Title58/Chapter37/C58-37_2026050620260701.pdf

Retrieved

2026-10-31

Fingerprint

9e125ec4f481cc71

58-37-108 Schedules of controlled substances -- Schedules I through V -- Findings required
    -- Specific substances included in schedules.
    (1) There are established five schedules of controlled substances known as Schedules I, II, III, IV,
        and V, which consist of substances listed in this section.
    (2) Schedules I, II, III, IV, and V consist of the following drugs or other substances by the official
        name, common or usual name, chemical name, or brand name designated:
      (a) Except as provided in Subsection (3), Schedule I:
(iii) Unless specifically excepted or unless listed in another schedule, any material, compound,
             mixture, or preparation that contains any quantity of the following hallucinogenic
             substances, or that contains any of their salts, isomers, and salts of isomers when the
             existence of the salts, isomers, and salts of isomers is possible within the specific chemical
             designation; as used in this Subsection (2)(a)(iii) only, "isomer" includes the optical, position,
             and geometric isomers:
          (A) Alpha-ethyltryptamine, some trade or other names: etryptamine; Monase; α-ethyl-1H-
                indole-3-ethanamine; 3-(2-aminobutyl) indole; α-ET; and AET;
            (B) 4-bromo-2,5-dimethoxy-amphetamine, some trade or other names: 4-bromo-2,5-
                dimethoxy-α-methylphenethylamine; 4-bromo-2,5-DMA;
            (C) 4-bromo-2,5-dimethoxyphenethylamine, some trade or other names: 2-(4-bromo-2,5-
                dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB; 2C-B, Nexus;
            (D) 2,5-dimethoxyamphetamine, some trade or other names: 2,5-dimethoxy-α-
                methylphenethylamine; 2,5-DMA;
            (E) 2,5-dimethoxy-4-ethylamphetamine, some trade or other names: DOET;
            (F) 4-methoxyamphetamine, some trade or other names: 4-methoxy-α-
                methylphenethylamine; paramethoxyamphetamine, PMA;
            (G) 5-methoxy-3,4-methylenedioxyamphetamine;
            (H) 4-methyl-2,5-dimethoxy-amphetamine, some trade and other names: 4-methyl-2,5-
                 dimethoxy-α-methylphenethylamine; “DOM”; and “STP”;
            (I) 3,4-methylenedioxy amphetamine;
            (J) 3,4-methylenedioxymethamphetamine (MDMA);
            (K) 3,4-methylenedioxy-N-ethylamphetamine, also known as N-ethyl- alpha-
                 methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, MDEA;
            (L) N-hydroxy-3,4-methylenedioxyamphetamine, also known as N-hydroxy-alpha-
                 methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA;
            (M) 3,4,5-trimethoxy amphetamine;
            (N) Bufotenine, some trade and other names: 3-(β-Dimethylaminoethyl)-5-hydroxyindole;
                 3-(2-dimethylaminoethyl)-5-indolol; N, N-dimethylserotonin; 5-hydroxy-N,N-
                 dimethyltryptamine; mappine;
            (O) Diethyltryptamine, some trade and other names: N,N-Diethyltryptamine; DET;
            (P) Dimethyltryptamine, some trade or other names: DMT;
            (Q) Ibogaine, some trade and other names: 7-Ethyl-6,6β,7,8,9,10,12,13-octahydro-2-
                 methoxy-6,9-methano-5H-pyrido [1', 2':1,2] azepino [5,4-b] indole; Tabernanthe iboga;
            (R) Lysergic acid diethylamide;
            (S) Marijuana;
            (T) Mescaline;
            (U) Parahexyl, some trade or other names: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-
                 trimethyl-6H-dibenzo[b,d]pyran; Synhexyl;
            (V) Peyote, meaning all parts of the plant presently classified botanically as Lophophora
                 williamsii Lemaire, whether growing or not, the seeds thereof, any extract from any part of
                 such plant, and every compound, manufacture, salts, derivative, mixture, or preparation of
                 such plant, its seeds or extracts (Interprets 21 USC 812(c), Schedule I(c) (12));
            (W) N-ethyl-3-piperidyl benzilate;
            (X) N-methyl-3-piperidyl benzilate;
            (Y) Psilocybin;
            (Z) Psilocyn;
            (AA) Tetrahydrocannabinols, naturally contained in a plant of the genus Cannabis (cannabis
                 plant), except for marijuana as defined in Subsection 58-37-101(1)(w)(i)(E), as well
                 as synthetic equivalents of the substances contained in the cannabis plant, or in the
                 resinous extractives of Cannabis, sp. and/or synthetic substances, derivatives, and their
                 isomers with similar chemical structure and pharmacological activity to those substances
                 contained in the plant, such as the following: ∆1 cis or trans tetrahydrocannabinol, and
               their optical isomers ∆6 cis or trans tetrahydrocannabinol, and their optical isomers ∆3,4
               cis or trans tetrahydrocannabinol, and its optical isomers, and since nomenclature of these
               substances is not internationally standardized, compounds of these structures, regardless
               of numerical designation of atomic positions covered;
            (BB) Ethylamine analog of phencyclidine, some trade or other names: N-
               ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl)ethylamine, N-(1-
               phenylcyclohexyl)ethylamine, cyclohexamine, PCE;
            (CC) Pyrrolidine analog of phencyclidine, some trade or other names: 1-(1-phenylcyclohexyl)-
               pyrrolidine, PCPy, PHP;
           (DD) Thiophene analog of phencyclidine, some trade or other names: 1-[1-(2-thienyl)-
               cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine, TPCP, TCP; and
           (EE) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine, some other names: TCPy.

Instrument

Schedule III, depressants (Ketamine)

Source

https://le.utah.gov/xcode/Title58/Chapter37/C58-37_2026050620260701.pdf

Retrieved

2026-10-31

Fingerprint

fda440c49eb37c1d

(c) Schedule III:
(ii) Unless specifically excepted or unless listed in another schedule, any material, compound,
              mixture, or preparation that contains any quantity of the following substances having a
              depressant effect on the central nervous system:
           (A) any compound, mixture, or preparation containing amobarbital, secobarbital,
                pentobarbital, or any salt of any of them, and one or more other active medicinal
                ingredients that are not listed in any schedule;
           (B) any suppository dosage form containing amobarbital, secobarbital, or pentobarbital,
                or any salt of any of these drugs that is approved by the United States Food and Drug
                Administration for marketing only as a suppository;
           (C) any substance that contains any quantity of a derivative of barbituric acid or any salt of
                any of them;
           (D) Chlorhexadol;
           (E) Buprenorphine;
           (F) any drug product containing gamma hydroxybutyric acid, including its salts, isomers, and
                salts of isomers, for which an application is approved under the federal Food, Drug, and
                Cosmetic Act, Section 505;
           (G) Ketamine, its salts, isomers, and salts of isomers, some other names for ketamine: ± -2-
                (2-chlorophenyl)-2-(methylamino)-cyclohexanone;

Instrument

Abuse of psychotoxic chemical solvent

Source

https://le.utah.gov/xcode/Title76/Chapter9/C76-9-S1110_2026050620260506.html

Retrieved

2026-10-31

Fingerprint

7c89669c0128a9b3

76-9-1110. 

Abuse of psychotoxic chemical solvent.

(1)

(a)
As used in this section, "psychotoxic chemical solvent" includes any glue, cement, or other substance containing one or more of the following chemical compounds:

(i)
 acetone and acetate;

(ii)
amyl nitrite or amyl nitrate or their isomers;

(iii)
benzene, butyl alcohol, butyl nitrite, butyl nitrate, or their isomers;

(iv)
ethyl alcohol, ethyl nitrite, or ethyl nitrate;

(v)
ethylene dichloride;

(vi)
isobutyl alcohol;

(vii)
methyl alcohol;

(viii)
methyl ethyl ketone;

(ix)
n-propyl alcohol;

(x)
pentachlorophenol;

(xi)
petroleum ether;

(xii)
propyl nitrite or propyl nitrate or their isomers;

(xiii)
toluene;

(xiv)
xylene; or

(xv)
another chemical substance capable of causing a condition of intoxication, inebriation, excitement, stupefaction, or the dulling of the brain or nervous system as a result of the inhalation of the fumes or vapors of such chemical substance.

(b)
Terms defined in Sections
76-1-101.5
 and
76-9-1101
 apply to this section.

(2)
Except as provided in Subsection
(4)
, an actor commits abuse of psychotoxic chemical solvent if:

(a)
for the purpose of causing a condition of intoxication, inebriation, excitement, stupefaction, or the dulling of the actor’s brain or nervous system, the actor intentionally:

(i)
smells or inhales the fumes of a psychotoxic chemical solvent; or

(ii)
possesses, purchases, or attempts to possess or purchase a psychotoxic chemical solvent; or

(b)
the actor offers, sells, or provides a psychotoxic chemical solvent to another person, knowing that other person or a third party intends to possess or use that psychotoxic chemical solvent in violation of Subsection
(2)(a)
.

(3)
A violation of Subsection
(2)
 is a class B misdemeanor.

(4)
This section does not apply to:

(a)
the prescribed use, distribution, or sale of a psychotoxic chemical solvent for a medical or dental purpose; or

(b)
a controlled substance regulated by the provisions of Chapter 18, Part 2, Offenses Concerning Controlled Substances, or Title 58, Chapter 37, Controlled Substances.

Instrument

Abuse of nitrous oxide

Source

https://le.utah.gov/xcode/Title76/Chapter9/C76-9-S1111_2025050720250507.html

Retrieved

2026-10-31

Fingerprint

9d5a632f71fe8bb8

76-9-1111. 

Abuse of nitrous oxide.

(1)

(a)
As used in this section, "nitrous oxide" means:

(i)
N2O, a colorless gas or liquid that is also referred to as dinitrogen monoxide, nitrogen oxide, or laughing gas; or

(ii)
any substance containing nitrous oxide.

(b)
Terms defined in Sections
76-1-101.5
 and
76-9-1101
 apply to this section.

(2)
Except as provided in Subsection (4), an actor commits abuse of nitrous oxide if the actor:

(a)
possesses nitrous oxide with the intent to breathe, inhale, or ingest the nitrous oxide for the purpose of:

(i)
causing a condition of intoxication, elation, euphoria, dizziness, stupefaction, or dulling of the senses; or

(ii)
in any manner changing, distorting, or disturbing the audio, visual, or mental processes;

(b)
knowingly or intentionally is under the influence of nitrous oxide; or

(c)
offers, sells, or provides nitrous oxide to another person, knowing that other person or a third party intends to possess or use the nitrous oxide in violation of Subsection
(2)(a)
 or
(b)
.

(3)
A violation of Subsection
(2)
 is a class A misdemeanor.

(4)

(a)
Subsection
(2)(b)
 does not apply to any person who is under the influence of nitrous oxide pursuant to an administration for the purpose of medical, surgical, or dental care by a person holding a license under state law that authorizes the administration of nitrous oxide.

(b)
Subsection
(2)(c)
 does not apply to any person who:

(i)
administers nitrous oxide for the purpose of medical, surgical, or dental care; and

(ii)
holds a license under state law that authorizes the administration of nitrous oxide.

Instrument

Definitions - Controlled substance analog

Source

https://le.utah.gov/xcode/Title58/Chapter37/C58-37-S2_2025050720250507.pdf

Retrieved

2026-07-20

Fingerprint

4e0392801725d222

(i) “Controlled substance analog” means: (A) a substance the chemical structure of which is substantially similar to the chemical structure of a controlled substance listed in Schedules I and II of Section 58-37-4, a substance listed in Section 58-37-4.2, or in Schedules I and II of the federal Controlled Substances Act, Title II, P.L. 91-513; (B) a substance that has a stimulant, depressant, or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant, or hallucinogenic effect on the central nervous system of controlled substances listed in Schedules I and II of Section 58-37-4, substances listed in Section 58-37-4.2, or substances listed in Schedules I and II of the federal Controlled Substances Act, Title II, P.L. 91-513; or (C) A substance that, with respect to a particular individual, is represented or intended to have a stimulant, depressant, or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant, or hallucinogenic effect on the central nervous system of controlled substances listed in Schedules I and II of Section 58-37-4, substances listed in Section 58-37-4.2, or substances listed in Schedules I and II of the federal Controlled Substances Act, Title II, P.L. 91-513. (ii) “Controlled substance analog” does not include: (A) a controlled substance currently scheduled in Schedules I through V of Section 58-37-4; (B) a substance for which there is an approved new drug application; (C) a substance with respect to which an exemption is in effect for investigational use by a particular person under Section 505 of the Food, Drug, and Cosmetic Act, 21 U.S.C. 355, to the extent the conduct with respect to the substance is permitted by the exemption; (D) any substance to the extent not intended for human consumption before an exemption takes effect with respect to the substance; (E) any drug intended for lawful use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals, which contains ephedrine, pseudoephedrine, norpseudoephedrine, or phenylpropanolamine if the drug is lawfully purchased, sold, transferred, or furnished as an over-the-counter medication without prescription; or (F) dietary supplements, vitamins, minerals, herbs, or other similar substances including concentrates or extracts, which are not otherwise regulated by law, which may contain naturally occurring amounts of chemical or substances listed in this chapter, or in rules adopted pursuant to Title 63G, Chapter 3, Utah Administrative Rulemaking Act.